Intravenous Infusions Plc

GHSE:IIL Stock Report

Market Cap: GH₵13.7m

Intravenous Infusions Past Earnings Performance

Past criteria checks 2/6

Intravenous Infusions's earnings have been declining at an average annual rate of -8.7%, while the Pharmaceuticals industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 26.9% per year. Intravenous Infusions's return on equity is 5.3%, and it has net margins of 3.1%.

Key information

-8.7%

Earnings growth rate

-9.9%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate26.9%
Return on equity5.3%
Net Margin3.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Intravenous Infusions makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

GHSE:IIL Revenue, expenses and earnings (GHS Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24301130
31 Mar 24312130
31 Dec 23313120
30 Sep 23281120
30 Jun 23240120
31 Mar 2322-2110
31 Dec 2220-4110
31 Dec 2123190
31 Dec 2021180
31 Dec 1923290
31 Dec 1820370
30 Sep 1820370
30 Jun 1820470
31 Mar 1818360
31 Dec 1716350
30 Sep 1715250
30 Jun 1712140
31 Mar 1711130
31 Dec 1611130
30 Sep 169030
30 Jun 169120
31 Mar 168020
31 Dec 158-120
30 Sep 157030
31 Dec 146-120
31 Dec 135020

Quality Earnings: IIL has high quality earnings.

Growing Profit Margin: IIL became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IIL's earnings have declined by 8.7% per year over the past 5 years.

Accelerating Growth: IIL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IIL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.8%).


Return on Equity

High ROE: IIL's Return on Equity (5.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies